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1. Introduction 
There are over one hundred species of plants of the genus Erythrina in the tropics and 
many of them are native to the American continent (Neill 1988). Erythrina species are 
known to produce alkaloids, flavonoids and terpenes (Garcia-Mateos et al., 1998). As with 
other species of Erythrina, alkaloids appear to be one of the main constituents mulungu 
(Parsons and Palframan, 2010). Mulungu (Erythrina mulungu) is a branched tree native to 
Brazil, growing in rain-forestry of Amazonia. Since its flowers are the same red color as 
coral, the plant is sometimes also called "flor de coral" and in English literature "coral 
tree".  The designation Erythrina also includes the species Erythrina velutina, endemic to 
the semi-arid regions of Northeastern Brazil, and Erythrina mulungu, a plant native to 
Southern Brazil. 
In native herbal medicine, a leaf or bark decoction or tincture from mulungu  has long been 
used in folk medicine due to their tranquilizing effects and as natural sedative. It is also 
anxiolytic and antibacterial (Garín-Aguilar et al., 2000). In both Brazil and Peru mulungu is 
used for epilepsy (Vasconcelos et al., 2007). Practitioners in the United States use mulungu 
to quiet hysteria from trauma or shock, as a mild sedative to calm the nervous system, to 
treat insomnia and promote healthy sleeping patterns. Anxiety disorders are among the 
most prevalent psychiatric diseases and mulungu offers novel therapy chance (Balbani et al., 
2009; Patocka, 2009). Latest the present results suggest that Erythrina has anxiolytic-like 
effects on a specific subset of defensive behaviors, particularly one that has been related in 
clinical terms to generalized anxiety. These observations support the popular use of extracts 
of the plant as tranquilizing agents. 
2. Ethnobotany 
Erythrina  is a genus of flowering plants in the pea family, Fabaceae. It contains about 130 
species, which are distributed in tropical and subtropical regions worldwide. They are trees, 
growing up to 30 m in height. The generic name is derived from the Greek word εǒυθǒóǓ 
(erythros), meaning "red", referring to the flower color of certain species. These trees are 
religious for some ethnic minority and are used as floral emblems in many countries. For 
example Cockspur Coral Tree (E. crista-galli) is the national flower of Argentina and 
Uruguay. The Coastal Coral Tree (E. caffra) is the official city tree of Los Angeles, California. 
The state trees of Mérida and Trujillo in Venezuela are "bucaré ceibo" (E. poeppigiana) and 
Purple Coral Tree ("bucaré anauco", E. fusca), respectively. E. variegata is used as floral 
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emblem in Yonabaru, Okinawa. Some coral trees are used widely as street and park trees, 
especially in tropical countries. These trees are very suitable as "frame tree" for vanilla vines 
to grow up on or are used as "shade trees" in coffee or cocoa plantations (Westley and 
Powell, 1993). The plants of the genus Erythrina were used in Pre-Columbian America in 
traditional medicine (Towle, 2007) to calm agitation and for insomnia and other disorders of 
the nervous system. 
3. Ethnopharmacology 
Pharmacological assays performed with the alkaloids of Erythrina americana have shown 
anticonvulsant, hypnotic and analgesic effects (Garín-Aguilar et al., 2000; Koné et al., 2004). 
The species Erythrina glauca and Erythrina lysistemon have been reported to possess antiviral, 
antibacterial, and estrogenic activity (Ito, 1999; Tanee et al., 2007). Furthermore, analgesic 
and anti-inflammatory effects were observed for an aqueous extract of the stem bark of 
Erythrina senegalensis (Saidu et al., 2000).  
Erythrina mulungu, tree high up to 10 m, is at home in South America. In Brasilia it is known 
as colorines, chilicote or tzompanquahuitl (Agra et al.  2007). In herbal medicine, a leaf or bark 
decoction or tincture from mulungu is considered to calm agitation and other disorders of 
the nervous system, including insomnia (Rodrigues and Carlini, 2003; Vasconcelos et al., 
2007). Mulungu also decreased blood pressure and normalize heart arythmia (Begossi et al., 
2004). There have also been some reports on the therapeutic use of the plant's inflorescence 
by herbal practitioners (Onusic et al. 2003). In Pre-Columbian civilizations decoction from 
the bark of this tree was used for suppression of fight fear and wartime hardship (Duke, 
2008). At present, mulungu is used in the area of South America, mainly in Brasilia and 
Peru, as sedative and also in epilepsy (Teixeira-Silva et al., 2008).  
People's healers and some practitioners in The United States use mulungu to quiet hysteria 
from trauma or shock, as a mild, hypnotic sedative to calm the nervous system, to treat 
insomnia and promote healthy sleeping patterns, to regulate heart palpitations, and to treat 
hepatitis and liver disorders. Nevertheless, despite its wide popular utilization, the 
supposed therapeutic properties of Erythrina mulungu only recently began to be evaluated in 
preclinical studies. 
4. Chemistry of Erythrina constituents 
The chemicals constituents of mulungu have been studied extensively after modern medical 
science find health potential of this biomedicine. In this biological material have been found 
large amounts of novel flavonoids, triterpenes, and alkaloids (Da-Cunha et al., 1996; 
Majinda et al., 2005; Cui et al., 2009). The genus Erythrina is very rich in secondary 
metabolites particularly of the flavonoids class. A literature survey showed the presence of 
flavanones, flavonols, chalcones, cinnamoylphenols, stilbenoids, isoflavones, isoflavans, 
isoflavanones, pterocarpans, isoflav-3-enes, 3-phenoxychromones, coumastans, 3-phenyl-
coumarins, lignans, cinnamate esters, simple phenolics, triterpenes, sesquiterpenes, long-
chain carboxylic acids, and long-chain alcohols (Majinda et al., 2005). Flavonoids represent a 
group of very active chemicals with various properties and are almost always present in 
Erythrina species. 
The most considerable group of biologicaly active compounds of mulungu are alkaloids 
(Ozawa et al. 2009). The alkaloids have been found in 78 of 107 species in the genus 
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Erythrina; mulungu is documented with 20 isoquinoline alkaloids (Tanaka et al., 2008; 
Parsons and Palframan, 2010). The alkaloids accumulated not only at the end of maturation 
in the seeds but also in young tissues. On a dried basis, a high content of alkaloids was 
observed in flowers and dry seeds in comparison to low levels in dry pods. The highest 
concentrations were found in the mature seeds (García-Mateos et al., 1996). Many of these 
have demonstrated anti-inflammatory, cardioactive, narcotic, and sedative activities 
(Parsons and Palframan, 2010).  
The pivotal structure of erythrinan alkaloids is tetraheterocyclic nitrogen compound with 
tetrahydroisoquinoline moiety called erythrinane (I) (Amer et al., 1991). Compounds of 
these structure were known for a long time (Koniuszy et al., 1949), but until medical 
science research of mulungu ignified concern over these alkaloids. Heft of erythrinan 
alkaloids are derivatives of I substituted at nucleus A and D by hydroxyl or alkoxy 
groups. The most considerable erythrinan alkaloids are erysotrine (II), erythravine (III), 
erysodine (IV), and erysopine (V) (Fig. 1) (Flausino et al., 2007a,b). For ever new 
erythrinan alkaloids are recovered (Tanaka et al., 2008; Cui et al., 2009, Parsons and 
Palframan, 2010).  
 
 
 
Alkaloid R1 R2 R3 
I H H H 
II OCH3 OCH3 OCH3 
III OCH3 OCH3 OH 
IV OH OCH3 OCH3 
V OH OH OCH3 
Fig. 1. Chemical structures of erythrinan alkaloids.  Erythrinan alkaloids are derived from 
tetraheterocyclic nitrogen compound with tetrahydroisoquinoline moiety called erythrinane 
(I). Heft of erythrinan alkaloids are derivatives of I substituted at nucleus A and D by 
hydroxyl or alkoxy groups. The most considerable erythrinan alkaloids are erysotrine (II), 
erythravine (III), erysodine (IV), and erysopine (V). 
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5. Toxicology 
Mulungu is relatively safe remedy. Acute oral toxicity (LD50) of aqueous extract of stem bark 
of E. variegata  was 425 mg/kg in mice (Pitchaiah et al., 2010). Lollato et al. (2010) estimated 
for extracts of  E. speciosa LD50 value for mice as being higher than 2000 mg/kg.  
The toxicity of chloroform stem bark extract of Erythrina senegalensis DC, a medicinal plant 
with anti-inflammatory activity, was studied in vivo and in vitro by Udem and co-workers 
(2010). The LD50 intraperitoneal of the extract was 526 mg/kg after an acute toxicity test 
(24 h). A brine shrimp lethality test with the extract gave LC50 of 60.86 ppm. The chronic 
studies revealed alterations in the levels of biochemical markers of hepatic and cardiac 
damage. The alterations were, however, not significant except in the group fed the highest 
inclusion of the extract (1.0 g extract/kg feed) where significant (p < 0.05) increases in the 
activities of alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase 
were observed. Hematological assessments of mice in this group showed significant 
(p < 0.05) decreases in the red blood cell count and the packed cell volume. Increases in the 
relative weights of the liver and heart were also significant (p < 0.05). Lipid peroxidation 
product levels assayed as malondialdehyde was significantly (p < 0.05) elevated in the 
groups fed 0.5 and 1.0 g/kg of feed at day 84. Significant histopathological changes like 
myocardial hemorrhages and degeneration of hepatocytes were observed in the heart and 
liver respectively. 
Mulungu is less toxic than most of synthetic tranquilizers, e.g. LD50 value for diazepam in 
mice at peroral administration is 49 mg/kg (Hogskilde et al., 1987). To evaluate the acute 
toxicity of the aqueous extract of Erythrina velutina leaves, which is frequently used in folk 
medicine as a tranquilizer, adult Wistar rats were treated per os with the limit dose of  
5 g/kg of the extract and then observed for 14 consecutive days. No animals died and  
no signs of toxicity were detected either during the behavioral observations or at  
the autopsies, what indicates a reasonable lack of toxicity for the extract (Craveiro et  
al., 2010). 
6. Biological activity  
The traditional use of mulungu for anxiety and stress has been validated by researchers in a 
few studies, where it was shown to alter anxiety-related responses (Flausino et al. 2007a,b). 
An animal model (correlating to human generalized anxiety disorder, as well as panic 
disorder) was undertaken on a water-alcohol extract of mulungu (Vasconcelos et al. 2004; 
Ribeiro et al. 2006; Flausino et al. 2007a). Vasconcelos and co-workers (2004) studied the 
effects of hydroalcoholic extracts of both Erythrina velutina and Erythrina mulungu on the 
behavior of female mice submitted to the open-field test and to the elevated plus-maze after 
oral or intraperitoneal administration. The highest doses (800 mg/kg, oral, and 400 mg/kg, 
intraperitoneal) of the hydroalcoholic extracts decreased locomotor activity both in the 
open-field and in the elevated plus-maze test. The authors concluded that these results 
supported, at least in part, the popular use of the two species of Erythrina as tranquilizers in 
Brazilian folk medicine. Another study (Dantas et al., 2004) performed with intraperitoneal 
administration of an aqueous Erythrina velutina extract showed that the extract prolonged 
the duration of sleep induced by sodium pentobarbital at higher doses and blocked the 
acquisition of foot shock memory at lower doses. These results led the authors to propose 
that Erythrina velutina might interfere with the mnemonic process and might have a sedative 
action (Dantas et al., 4004). 
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The researchers reported that the mulungu extract had an effect similar to the commonly-
prescribed anti-anxiety drug diazepam (Onusic et al. 2003; Ribeiro et al. 2006; Teixeira-Silva 
et al. 2008). Raupp and co-workers (2008) administered orally the hydroalcoholic extract of 
the stem bark of Erythrina velutina in mice submitted to the following tests: elevated plus-
maze, forced swim, spontaneous locomotor activity, and habituation to active chamber. 
Chlordiazepoxide and imipramine were used as standard drugs. In the elevated plus-maze 
test, chronic, but not acute, Erythrina velutina (100 mg/kg) administration increased the 
percentage of open arm entries, an effect also seen in both acute and chronic treatments with 
chlordiazepoxide (7.5 mg/kg). In the forced swim test, only imipramine (25 mg/kg) 
decreased immobility time. Impairment of habituation was seen only with acute imipramine 
administration and with the lowest doses of Erythrina velutina extract tested in acute 
(10 mg/kg) and chronic (50 mg/kg) administrations. These results suggest that chronic 
administration of the hydroalcoholic extract of the stem bark of Erythrina velutina exerts an 
anxiolytic-like effect on mice, and it could serve as a new approach for the treatment 
anxiety, although it may have an amnesic effect at low doses. 
It was suggested in many studies that the alkaloids in Erythrina may alter GABAergic 
neurotransmission (Ribeiro et al, 2006; Teixeira-Silva et al. 2008; Khanum and Razack, 
2010). GABA acts as a neurotransmitter in the brain and abnormalities with its function  
is implicated in diseases including epilepsy, anxiety, and depression. Nevertheless, 
mechanism of anxiolytic effect of erythrina alkaloids is evidently different from 
diazepines. These alkaloids induced contractions seem to involve GABAA receptor 
activation, acetylcholine release, muscarinic receptor activation, augmentation of Ca2+ 
entry through L-type calcium channels, and calcium release from the intracellular stores. 
These findings provide further support for Erythrina velutina traditional uses (Carvalho  
et al. 2009).  
Hydroalcoholic extracts from the stem bark of rythrina  velutina and Eerythrina mulungu have 
anticonvulsant effects only in the strychnine-induced seizure model, suggesting their 
possible action in glycine system and a potentiation of pentobarbital sleeping time, 
suggesting depressant action in the CNS (Vasconcelos et al. 2007). Data of Dantas and co-
workers (2004) showed that the crude extract of  E. velutina at lower doses interferes with 
mnemonic process for different tasks, while at higher doses, the sedative and 
neuromuscular blocking actions are the main effects. Anticonvulsant profile of erythrina 
alkaloids was recently studied by Faggion et al. (2011). They isolated the alkaloids (+)-
erythravine and (+)-11-α-hydroxy-erythravine from the flowers of Erythrina mulungu and 
evaluated the action of these compounds against chemically induced seizures in rats 
(Faggion et al. 2011). These results showed that the administration of different doses of (+)-
erythravine inhibited seizures evoked by bicuculline, pentylenetetrazole, and kainic acid at 
maximum of 80, 100, and 100%, respectively, whereas different doses of (+)-11-α-hydroxy-
erythravine inhibited seizures at a maximum of 100% when induced by bicuculline, NMDA, 
and kainic acid, and, to a lesser extent, pentylenetetrazole (60%). All animals were protected 
against death when treated with different doses of (+)-11-α-hydroxy-erythravine in the tests 
using the four chemical convulsants. Identical results were obtained when using (+)-
erythravine in the tests of bicuculline, NMDA, and pentylenetetrazole, and, to a lesser 
extent, kainic acid.  
Further research has validated the traditional use of mulungu as an antimicrobial agent for 
throat and urinary infections. Mulungu has demonstrated antibacterial activity against 
Escherichia coli, Staphylococcus aureus, and antimycobacterial activity against Mycobacterium 
fortuitum and M.  smegmatis (Virtuoso et al., 2005; Ferreira de Lima et al., 2006).  Some 
www.intechopen.com
 
 Anxiety and Related Disorders 
 
286 
isoflavonoids, mainly erycristagallin (3,9-dihydroxy-2,10-di(gamma,gamma-dimethylallyl)-
6a,11a-dehydropterocarpan), isolated from Erythrina variegata have antibacterial activita 
against cariogenic oral bacteria (Sato et al., 2003). The findings indicate that erycristagallin 
has a potential as potent phytochemical agent for prevention of dental caries by inhibiting 
the growth of cariogenic bacteria and by interfering with incorporation of glucose 
responsible for production of organic acids. 
Two new compounds with antibacterial effect, erybacin A and erybacin B, were isolated 
from the roots of Erythrina herbacea. Their structures were established on the basis  
of spectroscopic analyses. Erybacin A is a rare, naturally occurring 1-hydroxy-1,3-
diphenylpropan-2-one derivative. The isolated compounds were evaluated for their 
antibacterial activity against 13 strains of methicillin-resistant Staphylococcus aureus (MRSA). 
The new compound erybacin B showed a potent bactericidal activity against MRSA (Tanaka 
et al., 2010b). 
Hydroalcoholic extracts from the stem bark and leaves of Erythrina  velutina and Erythrina 
mulungu have also antinociceptive effects which was not reversed by naloxone, i.e. these are 
independent of the opioid system (Vasconcelos et al., 2003; Marchioro et al., 2005). 
Alkaloid erysodine is a competitive antagonist at neuronal nicotinic acetylcholine receptors 
(Mansbach et al., 2000). The potent and competitive nature of erysodine's antagonism 
together with its ability to enter the brain after systemic administration suggest that 
erysodine may be a useful tool in characterizing neuronal nicotinic acetylcholine receptors 
(Decker et al., 1995). Recent findings show that erysodine and also dihydro-beta-
erythroidine are potent and selective competitive inhibitors of alpha4beta2 nicotinic 
acetylcholine receptors (Iturriaga-Vásquez et al., 2010).  
Erythrinan alkaloids cristanine A and cristanine B were isolated from the bark of  Erythrina 
crista-galli. In Brazil, the bark of the title tree is used for the treatment of rheumatism and 
hepatitis as well as for sedation and hypnogenesis. However, the title alkaloids cristanine A 
and B are inactive concerning the inhibitory activity on lipopolysaccharide-induced nitric 
oxide production (Ozawa et al., 2010). Probably erythrinan alkaloids are also responsible for 
the antiinflammatory and analgesic effects of the ethanolic extract of Erythrina indica 
(Rajeev eta l. 2010). Erythrina indica leaves are traditionally used in Kerala to treat 
inflammation, ulcers, earache etc. 
7. Current practical use of Erythrina  
Mulungu, drug from the tree Erythrina mulungu, is not very widely known or used in 
advanced countries. Mostly appearing as an ingredient in only a few herbal formulas for 
anxiety or depression. Erythrina plants produce alkaloids, flavonoids and terpenes and are 
commonly used in folk medicine due to their tranquilizing effects. Currently, the most 
widely prescribed medications for anxiety disorders are benzodiazepines. However, the 
clinical uses of benzodiazepines are limited by their side effects such as psychomotor 
impairment, potentiation of other central depressant drugs and dependence liability. 
Therefore, the development of new medications processing anxiolytic effect without the 
complications of benzodiazepines would be of great importance in the treatment of anxiety 
related disorders. 
The use of herbal medicines by physicians in Europe, Asia, and America, exploring their 
traditional remedies to find a suitable cure of these ‘mind affecting diseases’ and herbal 
medicines are often considered to be gentle and safe alternative to synthetic drugs. 
Nevertheless, till this time no relevant clinical study exist.      
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Recently many studies of other Erythrina species from different parts of world appeared. 
These studies show that bioactive products of these trees may be useful in modern medicine 
also in other statements. From the bark of Erythrina addisoniae new flavonoids of stilbenoide 
type were isolated. These compounds are strong imhibitors of viral neuraminidases. Quite 
new compound, which is a formylated stilbenoid derivative, exhibited strong inhibition of 
both influenza H1N1 and H9N2 neuraminidases with IC50 values of 8.80 ± 0.34 μg/mL and 
7.19 ± 0.40 μg/mL, respectively (Nguyen et al., 2010).   
From the bark of Erythrina abyssinica has been isolated new coumestans and benzofurans 
with stimulatory effects on AMP-activated protein kinase (AMPK) (Nguyen et al., 2010) 
which has been proposed as a therapeutic target for the treatment of metabolic syndrome 
including obesity and type-2 diabetes. These results suggest that benzofurans and 
coumestans may be new lead compounds for regulating the AMPK enzyme. Prenylated  
flavanones from the same of source inhibited protein tyrosine phosphatase PTP1B activity in 
an in vitro assay with IC50 values ranging from 15.2 ± 1.2 to 19.6 ± 2.3 μM, whereas very 
known potent inhibitor of PTP1B known as RK-682 (Hamaguchi et al., 1995) used as a 
positive control displayed an IC50 value of 4.7 ± 0.5 μM (Long et al., 2010). 
Two new dimethylpyrano-isoflavones, named erymildbaedin A and B, were isolated from 
the stem bark of Eyrthrina mildbraedi - Cameroonian medicinal plant. Some of them strongly 
inhibited the growth of human breast, prostate, and endometrial adenocarcinoma cell 
lines (Tchokouaha et al. 2010). 
Another flavonoids with the antibacterial activity were isolated from Erythrina caffra, 
deciduous subtropical tree indigenous to South Africa. All the compounds were active 
against both Gram-negative and Gram-positive bacteria. The minimum inhibitory 
concentration values obtained (MIC) ranged from 3.9 μg/mL to 125 μg/mL 
(Chukwujekwu et al., 2010). A new bis-isoflavonoid, biseryvarin A, was isolated from the 
roots of Erythrina variegata. Biseryvarin A is the first dimeric isoflavonoid possessing 
isoprenoid groups from the genus Erythrina. Biseryvarin A showed low activity MRSA. The 
methanol extract of the bark of  Erythrina variegata showed significant anti-malarial activity 
toward Plasmodium falciparum in vitro using the lactate dehydrogenase assay. The ethyl 
acetate fraction showed the most activity, exhibiting equipotency against both strains of 
parasite with IC50 of 23.8 µg/mL against 3D7 and 9.3 µg/mL against K1. Furthermore, by 
using the anti-malarial activity to follow separation, the ethyl acetate fraction was separated 
by combination of column chromatography to yield an active compound. The chemical 
structure of active compound was determined on the basis of spectroscopic evidences and 
comparison with those previously reported and identified as an isoflavonoid, warangalone. 
The warangalone showed anti-malarial activity against both strains of parasite used with 
IC50 of 4.8 µg/mL against 3D7 and 3.7 µg/mL against K1 (Herlina et al., 2009). Next 
flavonoids were isolated from Erythrina vogelii, a Cameroonian medicinal plant (Ali et al. 
2010), in Erythrina senegalensis were found hepatoprotective flavonoids (Njayou et al., 2010) 
with low toxicity (Atsamo et al., 2010). Flavonoids of pterocarpane-type with antibacterial, 
antiplasmodial and cytotoxic activities, were isolated from the stems of Erythrina fusca 
(Innok et al., 2010). 
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